Astrazeneca

FromAstraZeneca ([email protected])
Subject (149)Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic
Preheader (149)Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic
Typography
Arial
Colors
Text Analysis
Body Words161
Subject Words23
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images6
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px796 px
X-Spam Score-0.1
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeOvernight

Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic

Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic
Enhertu plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP as 1st-line therapy in patients with HER2-positive metastatic